Moscow: The trial mixes the first dose of Russia’s sputnik vaccine made by AstraZeneca’s shot does not reveal serious side effects and there are no subsequent Coronavirus cases among volunteers, Russian direct investment funds (RDIF) on Friday.
The trial involved 50 people and began in Azerbaijan in February, RDIF, who was responsible for marketing Vaksin Sputnik V abroad, said in the statement.
Full results of the trial, including data on immune response produced by combination vaccines, will be published next month, RDIF said.
Good Sputnik V and AstraZeneca shots are virus vector vaccines based on the first dose followed by a booster.
Virus vector shots like that use a modified virus that is harmless as a vehicle, or vector, to bring genetic information that helps the body build immunity against infections in the future.
The first dose of Sputnik V is based on adenovirus type 26, while the Covid-19 vaccine astrazeneca, develops along with the University of Oxford, using vector adenovirus chimpanzees.
Russia on Monday gave a green light for clinical trials that combine English and Sputnik V shots to advance across five Russian clinics.